Related Experiment Videos
Metoprolol does not reduce platelet aggregability during sympatho-adrenal stimulation
P T Larsson1, G Olsson, B Angelin
1Department of Pharmacology, Karolinska Institute, Stockholm, Sweden.
European Journal of Clinical Pharmacology
|January 1, 1992
Summary
Metoprolol, a beta-blocker, did not inhibit platelet function in vivo during stress or adrenaline infusions. The study found no effect on key markers of platelet activity, suggesting beta-blockers may not impact cardiovascular disease pathophysiology via this mechanism.
Area of Science:
- Cardiovascular Pharmacology
- Hemostasis and Thrombosis
Background:
- Beta-adrenoceptor blockers may influence platelet function, a factor relevant to cardiovascular diseases.
- Assessing in vivo platelet function is challenging, with limited available data.
Purpose of the Study:
- To evaluate the effect of metoprolol on platelet aggregability in vivo and in vitro.
- To investigate metoprolol's impact on platelet function during mental stress and adrenaline infusion.
Main Methods:
- A double-blind, placebo-controlled, cross-over study in 10 healthy males.
- Assessed in vivo platelet function via ex vivo filtragometry and urinary markers (HMW beta-TG, 11-dehydro-TxB2).
- Also measured in vitro platelet aggregability and urinary prostacyclin metabolite (2,3-dinor-6-keto-PGF1 alpha).
Main Results:
- Adrenaline infusion increased in vivo platelet aggregability and urinary HMW beta-TG.
- Metoprolol did not alter in vivo platelet function markers (filtragometry, urinary HMW beta-TG, 11-dehydro-TxB2).
- Metoprolol tended to enhance the stress response in ex vivo filtragometry.
Conclusions:
- Metoprolol (200 mg/day) did not inhibit platelet function in vivo under stress or adrenaline challenge.
- The findings suggest beta-blockers may not impact cardiovascular pathophysiology through direct inhibition of platelet activity.
- Further research is needed to fully elucidate the relationship between beta-blockers and platelet function.